Heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-20. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Renin is usually measured as the plasma renin activity (PRA). PRA is measured specially in case of certain diseases that present with hypertension or hypotension. PRA is also raised in certain tumors. A PRA measurement may be compared to a plasma aldosterone concentration (PAC) as a PAC/PRA ratio.
=== Pregnancy === Ketoconazole is categorized as pregnancy category C (Risk not ruled out) in the US. Research in animals has shown it to cause teratogenesis when administered in high doses. A subsequent trial in Europe failed to show a risk to infants of mothers receiving ketoconazole.
Caffeine (stylised CAFFEINE; formerly Coffee Inn and Caffeine Roasters) is a coffeehouse chain headquartered in Vilnius, Lithuania. Founded in 2007, it is the largest branded coffee chain in the Baltic states, operating more than 100 cafés in Lithuania and additional stores in Latvia, Estonia, Norway and Denmark.
Sources: en.wikipedia.org
== Partnerships == The company entered into a co-marketing and sales agreement with Thermo Fisher Scientific in November 2024 to promote the integration of Seer’s Proteograph system with Thermo Fisher’s Orbitrap mass spectrometers. In June 2025, Seer announced a collaboration with Korea University and major Korean cancer centers, including Seoul National University Hospital and Samsung Medical Center. The partnership will support a large-scale plasma proteomics study aimed at identifying blood-based biomarkers for cancers in young adults. The study will utilize Seer’s Proteograph platform and a mass spectrometer from Thermo Fisher Scientific to analyze over 20,000 plasma samples.
=== Adverse drug reactions === Ritonavir exhibits hepatic activity. It induces CYP1A2 and inhibits CYP3A4 and CYP2D6. Concomitant therapy of ritonavir with a variety of medications may result in serious and sometimes fatal drug interactions. Due to it being a strong inhibitor (that causes at least a five-fold increase in the plasma AUC values, or more than 80% decrease in clearance) of both cytochrome P450 enzymes CYP2D6 and CYP3A4, ritonavir can severely potentiate and prolong the half-life and/or increase the blood concentration of phenobarbital, primidone, carbamazepine, phenytoin, PDE5 inhibitors like sildenafil, opioids such as hydrocodone, oxycodone, pethidine and fentanyl, antiarrhythmic agents such as amiodarone, propafenone and disopyramide, immunosuppressants such as tacrolimus, voclosporin and sirolimus, neuroleptics like lurasidone and pimozide, as well as some chemotherapeutic agents, benzodiazepines and some ergot derivatives. The FDA has issued a boxed warning for this type of drug interaction. CYP3A4 inducers can counteract the inhibiting effects of ritonavir and lead to drastically reduced levels of "boosted" drugs, increasing the risk of developing drug resistance. Other CYP3A4 inhibitors may have an additive effect with ritonavir, causing increased drug levels.
=== Televisions === QLED TVs have been starting to include cadmium in construction. Some companies have been looking to reduce the environmental impact of human exposure and pollution of the material in televisions during production.
Sources: en.wikipedia.org
== Research == Filorexant was studied for but was not found to be effective in the treatment of diabetic neuropathy, migraine, and major depressive disorder in phase 2 clinical trials. Seltorexant is under development for treatment of major depressive disorder however and is in phase 3 trials for this indication. Also, suvorexant is in a phase 4 trial for use as an adjunct to antidepressant therapy in people with major depressive disorder and residual insomnia.
She had been born and brought up in Llangadog, as had her father, who is thought to be "Grandpa" in Thomas's short story A Visit to Grandpa's, in which Grandpa expresses his determination to be buried not in Llansteffan but in Llangadog. Evan worked on the railways and was known as Thomas the Guard. His family had originated in another part of Welsh-speaking Carmarthenshire, in the farms that lay around the villages of Brechfa, Abergorlech, Gwernogle and Llanybydder, and which the young Thomas occasionally visited with his father. His father's side of the family also provided the young Thomas with another kind of experience; many lived in the towns of the South Wales industrial belt, including Port Talbot, Pontarddulais and Cross Hands. Thomas had bronchitis and asthma in childhood and struggled with these throughout his life. He was indulged by his mother, Florence, and enjoyed being mollycoddled, a trait he carried into adulthood, becoming skilled in gaining attention and sympathy. But Florence would have known that child deaths had been a recurring event in the family's history, and it is said that she herself had lost a child soon after her marriage. If Thomas was protected and spoiled at home, however, the real spoilers were his many aunts and older cousins, those in both Swansea and the Llansteffan countryside. Some of them played an important part in both his upbringing and his later life, as Thomas's wife, Caitlin, has observed: "He couldn't stand their company for more than five minutes... Yet Dylan couldn't break away from them, either.
A widely cited moment from this period was her display of the WCC's Avalkoppam ("With Her") solidarity banner following a dance performance at the state government's awards ceremony in 2018, which was met with sustained applause.
== Ergothioneine derivatives == Various derivatives of ergothioneine have been reported in the literature, such as S-methyl-ergothioneine or selenium-containing selenoneine. The latter is made using the same biosynthetic pathway as ergothioneine when selenocysteine is present.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.